Artesunate Induces G0 / G1 Phase Arrest in Tumor Cells and Associates With Cyclin‐Dependent Kinase 4 ( CDK4 )
Cancer Medicine · 2026-05 · 15 (5)
DOI: 10.1002/cam4.71907 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 04.05.2026. Verfasst von Xinyu Chi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Communicable and Severe Diseases, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. Hauptthemen laut MEDLINE: Artesunate, Cyclin-Dependent Kinase 4, G1 Phase Cell Cycle Checkpoints, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangxi Natural Science Foundation, National Natural Science Foundation of China, Guangxi Key Research and Development Program.
Abstract (Originalsprache)
Background
Non‐small cell lung cancer ( NSCLC ) is the leading cause of cancer‐related death worldwide. Cyclin‐dependent kinase 4 ( CDK4 ) is a well‐validated oncogenic driver in NSCLC , yet current CDK4 inhibitors—predominantly based on the aminopyrimidine scaffold—are limited by structural homogeneity and the rapid emergence of acquired resistance, underscoring the need for novel chemotypes.
Methods
We employed a HuProt human proteome microarray to screen for direct cellular targets of artesunate, an FDA ‐approved artemisinin derivative. Candidate interactions were validated by molecular docking, surface plasmon resonance ( SPR ), and in vitro kinase assays. Functional effects were assessed in A549 and H1299 NSCLC cell lines using flow cytometry and Western blotting.
Results
Artesunate was identified as a direct binder of CDK4 , with molecular docking revealing a strong binding affinity (−7.069 kcal/mol). SPR analysis confirmed this interaction with a K d of 488 μM , and in vitro kinase assays demonstrated potent inhibition of CDK4 /Cyclin D3 activity ( IC 50 = 0.2943 μM ). Treatment with artesunate induced significant G0 / G1 cell cycle arrest in both A549 and H1299 cells. This effect was mediated through inhibition of the CDK4 –Rb– E2F axis, as evidenced by dose‐dependent suppression of Rb phosphorylation at Ser780 and Ser795.
Conclusion
Our findings establish artesunate as a structurally distinct, non‐aminopyrimidine CDK4 inhibitor with potent biochemical and cellular activity in NSCLC models. This work provides a promising therapeutic strategy to circumvent resistance associated with current CDK4 inhibitors and supports the repurposing of artesunate for CDK4 ‐driven cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center of Communicable and Severe Diseases, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
- Institute of Oncology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Förderung
- Guangxi Natural Science Foundation
- National Natural Science Foundation of China
- Guangxi Key Research and Development Program
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
Zitieren
APA
Chi, X., Chen, Q., Wang, G., Luo, H., Qu, S., & Zou, X. (2026). Artesunate Induces G0 / G1 Phase Arrest in Tumor Cells and Associates With Cyclin‐Dependent Kinase 4 ( CDK4 ). Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71907
Vancouver
Chi X, Chen Q, Wang G, Luo H, Qu S, Zou X. Artesunate Induces G0 / G1 Phase Arrest in Tumor Cells and Associates With Cyclin‐Dependent Kinase 4 ( CDK4 ). Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71907
BibTeX
@article{Chi2026,
author = {Chi, Xinyu and Chen, Qicong and Wang, Gang and Luo, Honglin and Qu, Shenhong and Zou, Xiaosu},
title = {Artesunate Induces G0 / G1 Phase Arrest in Tumor Cells and Associates With Cyclin‐Dependent Kinase 4 ( CDK4 )},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cam4.71907}
}
EUVIMED